Related Concept Videos
01:26Pneumothorax-I
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
01:17Other Pulmonary Disorders
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
01:27Pneumothorax-II
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:08Pneumothorax II: Pathophysiology
Pneumothorax means the presence of air in the pleural space — the thin potential gap between the visceral and parietal pleura. This condition disrupts the normal pressure balance that keeps the lungs inflated, leading to partial or complete collapse of the affected lung.Normal physiologyUnder normal conditions, the pleural space maintains a slightly negative intrapleural pressure, which keeps the lungs expanded against the chest wall. This negative pressure creates a delicate balance between...
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Related Experiment Video
Updated: May 31, 2026
06:03
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
Bleomycin lung: a case report.
1Medway Maritime Hospital, Windmill Road, Gillingham, Kent ME7 5NY, UK.
BMJ Case Reports
|June 21, 2011
Summary
Bleomycin chemotherapy, used for non-Hodgkin's lymphoma, can cause severe pulmonary toxicity. This case highlights fatal pulmonary fibrosis, emphasizing the need for vigilance during treatment.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Non-Hodgkin's lymphoma (NHL) is a cancer of the lymphatic system.
- Bleomycin is a chemotherapy agent used in treating certain lymphomas.
- Baseline fibrotic lung changes can be a complicating factor in chemotherapy toxicity.
Purpose of the Study:
- To report a case of fatal bleomycin-induced pulmonary toxicity.
- To highlight the diagnostic challenges in differentiating chemotherapy-induced lung injury from infection.
- To underscore the potential severity of bleomycin's adverse pulmonary effects.
Main Methods:
- Case report of a 69-year-old male with stage I NHL.
- Treatment with R-PMitCebo chemotherapy including bleomycin.
- Clinical presentation, imaging (CT, HRCT), and treatment response were analyzed.
Main Results:
- Patient developed progressive dyspnea, cough, and lethargy post-chemotherapy.
- Initial presentation mimicked community-acquired pneumonia but was unresponsive to treatment.
- High-resolution CT revealed widespread interstitial changes consistent with pulmonary fibrosis.
- Patient experienced respiratory failure and died despite intensive steroid treatment.
Conclusions:
- Bleomycin chemotherapy can induce severe, potentially fatal pulmonary fibrosis.
- Pulmonary toxicity from bleomycin may present insidiously and mimic infections.
- Vigilance and early recognition of bleomycin-induced lung injury are crucial for patient management.